All In MedTech

Device Trial Radar · NCT01874392

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) and Technosphere® Insulin Inhalation System From MannnKind Corp.

Last checked: Nov 20, 2026Latest source record: Nov 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

9

Actual

Start

Oct 2012

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Sansum Diabetes Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Juvenile Diabetes Research Foundation
First posted
Jun 11, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a feasibility study to assess the performance of an Artificial Pancreas (AP) device using the Artificial Pancreas System (APS©) platform for subjects with type 1 diabetes using rapid-acting insulin as well as preprandial inhaled insulin (Technosphere® Insulin Inhalation System by MannKind Corporation). The goal of this proposed study is to explore the feasibility of using multiple insulin delivery routes in order to mimic the physiology of both first- and second-phase insulin secretion. The intent is to exploit the rapid action achieved by inhaled insulin to compensate for part of the meals and utilize the conventional subcutaneous route for management of basal insulin and as second-phase meal-related insulin.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • Investigational inhaled insulin (Technosphere)Drug

    by MannKind Corp. IND 61,729

  • Artificial Pancreas (AP) device (APS©)Device

    Device includes: * OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp. * Dexcom® G4® CGM System (CGM) from Dexcom® Corp * Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.Time frame: 5 hours
  2. Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) Setting.Time frame: 25-28 hours
  3. Test the Safety of the AP Device While the Subject is Under Close Medical Supervision in the Clinical Research Center (CRC) SettingTime frame: 30 minutes

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sansum Diabetes Research Institute

    Santa Barbara, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.